Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.

Anna GalkinRavikumar SitaparaBryan ClemonsEduardo GarciaMichael KennedyDavid GuimondLaura L CarterAshley J DouthittRobin OsterhoutAneta GandjevaDeborah SleeLuisa Salter-CidRubin M TuderLawrence S Zisman

Published in: The European respiratory journal (2022)

Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary haemodynamic parameters, a reduction in NT-proBNP, reverse remodelling of pulmonary vascular pathology and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.

Keyphrases

pulmonary arterial hypertension
pulmonary hypertension
pulmonary artery
cystic fibrosis
early onset
combination therapy
chronic myeloid leukemia
replacement therapy